NCT00069862View on ClinicalTrials.gov

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

November 30, 2005

Conditions

Beta-Thalassemia

Interventions

DRUG

Deferitrin (GT56-252)

DRUG

desferoxamine (DFO)

Trial Locations (1)

10021

The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00069862 - Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia | Biotech Hunter | Biotech Hunter